$14.91 Million in Sales Expected for Adesto Technologies Corp (IOTS) This Quarter

Wall Street brokerages expect that Adesto Technologies Corp (NASDAQ:IOTS) will report sales of $14.91 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Adesto Technologies’ earnings, with the lowest sales estimate coming in at $14.84 million and the highest estimate coming in at $15.00 million. Adesto Technologies posted sales of $11.31 million during the same quarter last year, which suggests a positive year-over-year growth rate of 31.8%. The company is expected to issue its next quarterly earnings report on Wednesday, May 9th.

On average, analysts expect that Adesto Technologies will report full-year sales of $14.91 million for the current fiscal year, with estimates ranging from $69.50 million to $70.52 million. For the next year, analysts forecast that the company will post sales of $84.46 million per share, with estimates ranging from $83.70 million to $85.67 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Adesto Technologies.

How to Become a New Pot Stock Millionaire

Adesto Technologies (NASDAQ:IOTS) last released its earnings results on Tuesday, February 13th. The technology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. Adesto Technologies had a negative return on equity of 8.54% and a negative net margin of 10.14%. The business had revenue of $16.15 million for the quarter, compared to analyst estimates of $16.00 million.

IOTS has been the topic of several analyst reports. Northland Securities initiated coverage on Adesto Technologies in a report on Monday, March 19th. They set an “outperform” rating and a $10.50 target price on the stock. Zacks Investment Research lowered Adesto Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. TheStreet upgraded Adesto Technologies from a “d” rating to a “c-” rating in a report on Wednesday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Adesto Technologies in a report on Wednesday, January 17th. Finally, B. Riley began coverage on Adesto Technologies in a research report on Tuesday, March 20th. They set a “buy” rating and a $10.00 price target on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Adesto Technologies currently has an average rating of “Buy” and a consensus price target of $9.30.

In other Adesto Technologies news, VP Janet Wang sold 8,333 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $6.50, for a total transaction of $54,164.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Adesto Technologies by 5.6% during the second quarter. Vanguard Group Inc. now owns 126,943 shares of the technology company’s stock worth $578,000 after buying an additional 6,786 shares during the last quarter. Allianz Asset Management GmbH increased its position in Adesto Technologies by 9.0% during the fourth quarter. Allianz Asset Management GmbH now owns 143,947 shares of the technology company’s stock worth $928,000 after buying an additional 11,871 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Adesto Technologies in the third quarter valued at approximately $113,000. Monashee Investment Management LLC acquired a new position in shares of Adesto Technologies in the fourth quarter valued at approximately $122,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Adesto Technologies in the fourth quarter valued at approximately $162,000. 44.55% of the stock is currently owned by hedge funds and other institutional investors.

IOTS opened at $7.60 on Friday. Adesto Technologies has a 52-week low of $3.80 and a 52-week high of $9.20. The stock has a market cap of $161.52, a P/E ratio of -31.67 and a beta of 1.36. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.75 and a current ratio of 3.15.

COPYRIGHT VIOLATION WARNING: “$14.91 Million in Sales Expected for Adesto Technologies Corp (IOTS) This Quarter” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3337490/14-91-million-in-sales-expected-for-adesto-technologies-corp-iots-this-quarter.html.

Adesto Technologies Company Profile

Adesto Technologies Corporation is a provider of application-specific and ultra-low power non-volatile memory products. The Company optimizes its non-volatile memory products for Internet of Things (IoT), applications, including current and next-generation Internet-connected devices in the consumer, industrial, medical and wearables markets.

Get a free copy of the Zacks research report on Adesto Technologies (IOTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adesto Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adesto Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks Investment Research Upgrades SkyWest  to “Buy”
Zacks Investment Research Upgrades SkyWest to “Buy”
Regeneron  Downgraded to Sell at BidaskClub
Regeneron Downgraded to Sell at BidaskClub
HC Wainwright Analysts Give Rigel Pharmaceuticals  a $8.00 Price Target
HC Wainwright Analysts Give Rigel Pharmaceuticals a $8.00 Price Target
ValuEngine Lowers Simmons First National  to Sell
ValuEngine Lowers Simmons First National to Sell
Southside Bancshares  Downgraded by ValuEngine
Southside Bancshares Downgraded by ValuEngine
Head to Head Survey: Engie  versus Northwest Natural Gas
Head to Head Survey: Engie versus Northwest Natural Gas


© 2006-2018 Ticker Report. Google+.